利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.009 秒)

    ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY
    1.
    发明公开
    ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY 审中-公开
    抗体GD2-O乙酰化与促凋亡活性神经节苷脂

    公开(公告)号：EP3068802A1

    公开(公告)日：2016-09-21

    申请号：EP14806173.2

    申请日：2014-11-11

    申请人： OGD2 Pharma ,  Université de Nantes

    发明人： LE DOUSSAL, Jean-Marc ,  TERME, Mickaël ,  DORVILLIUS, Mylene

    IPC分类号： C07K16/30 ,  C07K16/46

    CPC分类号： C07K16/3084 ,  A61K2039/505 ,  C07K16/3015 ,  C07K16/3023 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention concerns an antibody, or functional fragment thereof, which binds specifically to the O-acetylated-GD2 ganglioside, said antibody comprising a) a light chain comprising three light chain complementary regions (CDRs) having the following amino acid sequences: the light chain CDR1: QSLLKNNGNTFL (SEQ id n°1), the light chain CDR2: KVS, the light chain CDR3: SQSTHIPYT (SEQ id n°2); and a light chain framework sequence from an immunoglobulin light chain, wherein said framework sequence comprises the human kappa (º)CL domain; and b) a heavy chain comprising three heavy chain complementary regions (CDRs) having the following amino acid sequences: the heavy chain CDR1: EFTFTDYY (SEQ id n°3), the heavy chain CDR2: IRNRANGYTT (SEQ id n°4), the heavy chain CDR3: ARVSNWAFDY (SEQ id n°5), and a heavy chain framework sequence from an immunoglobulin heavy chain, wherein said framework sequence comprises the CH2 and CH3 domains from a human IgG1, and a CH1 domain from a human IgG1, which is mutated so as to restore the pairing between CH1 and light chain that is typical of other human IgG subclasses or substituted by a CH1 domain from such non-IgG1 subclasses as human IgG2, IgG3 or IgG4; and its use in therapy.

    HUMAN IGG1 DERIVED ANTIBODY WITH PRO-APOPTOTIC ACTIVITY
    6.
    发明公开
    HUMAN IGG1 DERIVED ANTIBODY WITH PRO-APOPTOTIC ACTIVITY 审中-公开
    促凋亡活性人IgG1源抗体

    公开(公告)号：EP3068798A1

    公开(公告)日：2016-09-21

    申请号：EP14823891.8

    申请日：2014-11-11

    申请人： OGD2 Pharma

    发明人： DORVILLIUS, Mylène ,  LE DOUSSAL, Jean-Marc ,  TERME, Mickaël

    IPC分类号： C07K16/00

    摘要： A method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, includes: mutating the human CH1γ1 domain from the antibody, to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting the human CH1γ1 domain by the CH1 domain from a human IgG2 (CH1γ2), IgG3 (CH1γ3) or IgG4 (CH1γ4); the antibody obtained by such method, includes a) a light chain including the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen; and ii) a human kappa (κ)Constant (CL) domain; and b) a heavy chain including the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from the antigen; ii) the CH2 and CH3 domains from a human IgG1; and iii) the CH1 domain from a human IgG1, mutated to restore pairing between CHI and CL domains.